143 related articles for article (PubMed ID: 6118669)
1. Therapeutic selectivity of and predication of response to 2'-deoxycoformycin in acute leukaemia.
Prentice HG; Russell NH; Lee N; Ganeshaguru K; Blacklock H; Piga A; Smyth JF; Hoffbrand AV
Lancet; 1981 Dec; 2(8258):1250-4. PubMed ID: 6118669
[TBL] [Abstract][Full Text] [Related]
2. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
Poplack DG; Sallan SE; Rivera G; Holcenberg J; Murphy SB; Blatt J; Lipton JM; Venner P; Glaubiger DL; Ungerleider R; Johns D
Cancer Res; 1981 Sep; 41(9 Pt 1):3343-6. PubMed ID: 6973390
[TBL] [Abstract][Full Text] [Related]
4. Clinical consequences of 2'-deoxycoformycin treatment in patients with refractory adult T-cell leukaemia.
Yamaguchi K; Yul LS; Oda T; Maeda Y; Ishii M; Fujita K; Kagiyama S; Nagai K; Suzuki H; Takatsuki K
Leuk Res; 1986; 10(8):989-93. PubMed ID: 3489140
[TBL] [Abstract][Full Text] [Related]
5. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
6. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
[TBL] [Abstract][Full Text] [Related]
7. Deoxycoformycin in the treatment of leukemias and lymphomas.
Smyth JF; Prentice HG; Proctor S; Hoffbrand AV
Ann N Y Acad Sci; 1985; 451():123-8. PubMed ID: 3878113
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
Murphy SB; Stass S; Kalwinsky D; Rivera G
Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
[TBL] [Abstract][Full Text] [Related]
9. Membrane phenotype and response to deoxycoformycin in mature T cell malignancies.
Dearden CE; Matutes E; Hoffbrand AV; Ganeshaguru K; Brozovic M; Williams HJ; Traub N; Mills M; Linch DC; Catovsky D
Br Med J (Clin Res Ed); 1987 Oct; 295(6603):873-5. PubMed ID: 2890401
[TBL] [Abstract][Full Text] [Related]
10. Low-dose deoxycoformycin in lymphoid malignancy.
Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
[TBL] [Abstract][Full Text] [Related]
11. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
12. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
13. Studies on the biochemical sequelae of therapy in Thy-acute lymphoblastic leukaemia with the adenosine deaminase inhibitor 2' deoxycoformycin.
Russell NH; Prentice HG; Lee N; Piga A; Ganeshaguru K; Smyth JF; Hoffbrand AV
Br J Haematol; 1981 Sep; 49(1):1-9. PubMed ID: 6974003
[TBL] [Abstract][Full Text] [Related]
14. Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia.
Daenen S; Rojer RA; Smit JW; Halie MR; Nieweg HO
Br J Haematol; 1984 Dec; 58(4):723-7. PubMed ID: 6097297
[TBL] [Abstract][Full Text] [Related]
15. The treatment of hairy-cell leukaemia with 2'-deoxycoformycin.
Johnston JB; Glazer RI; Pugh L; Israels LG
Br J Haematol; 1986 Jul; 63(3):525-34. PubMed ID: 3488071
[TBL] [Abstract][Full Text] [Related]
16. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.
Winick N; Buchanan GR; Murphy SB; Yu A; Boyett J
Med Pediatr Oncol; 1988; 16(5):327-32. PubMed ID: 3263563
[TBL] [Abstract][Full Text] [Related]
17. Deoxycoformycin in therapy of refractory lymphoid neoplasms.
Ho AD; Thaler J; Kuse R; Willemze R; Mandelli F; Lauria F; Zittoun R; Stryckmans P
Onkologie; 1988 Feb; 11(1):35-7. PubMed ID: 3283623
[TBL] [Abstract][Full Text] [Related]
18. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.
Grever MR; Bisaccia E; Scarborough DA; Metz EN; Neidhart JA
Blood; 1983 Feb; 61(2):279-82. PubMed ID: 6600401
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacology of deoxycoformycin.
Major PP; Agarwal RP; Kufe DW
Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
[TBL] [Abstract][Full Text] [Related]
20. The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignancies.
Spiers AS
Blood Rev; 1987 Jun; 1(2):106-10. PubMed ID: 3332090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
